Clinical Outcomes of Remdesivir in COVID-19 Patients with Acute Kidney Injury or Chronic Kidney Disease: A Randomized Clinical Trial
Archives of Men's Health,
Vol. 7 No. 1 (2023),
22 January 2023
,
Page e7
https://doi.org/10.22037/mhj.v7i1.42554
Abstract
Background: remdesivir is an RNA polymerase inhibitor approved to treat moderate to severe Coronavirus Disease 2019 (COVID-19); however, it has not yet been authenticated to apply to patients with acute kidney injury (AKI) or chronic kidney disease (CKD). Regarding some positive results obtained from previous studies, we aimed to evaluate the efficacy and safety of remdesivir in patients with COVID-19 with severe renal impairment. Methods: In a randomized clinical trial, remdesivir was added to the standard regimen of treating patients with COVID-19 with AKI or CKD. 200 mg remdesivir was given on the first day of admission to 50 patients followed by 100 mg every other day until resolution of the symptoms. Clinical and paraclinical evaluation was performed daily and the findings were compared with the 50 patients on standard treatment regimen. Results: the rates of intensive care unit (ICU) admission (P: 0.02), and mortality (P: 0.007) were significantly reduced in patients who received remdesivir. Moreover, a substantial decrease of aspartate transaminase (AST) (P: 0.004), lactate dehydrogenase (LDH) (P: 0.004), ferritin (P: 0.007), erythrocyte sedimentation rate (ESR) (P<0.0001), alkaline phosphatase (ALP) (P: 0.006) were observed in the patients receiving remdesivir compared to the baseline values which was absent in case of non-remdesivir group. No serious side effects were observed, except for one patient who showed elevated liver enzymes. Conclusion: remdesivir appears to be well tolerated in patients with AKI and CKD. Administration of this drug resulted in reduced mortality and ICU admission as well as clinical and paraclinical improvement in these patients.
- COVID-19; Remdesivir
- Chronic Kidney Disease
- Acute Kidney Injury
How to Cite
References
Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. European journal of pharmacology. 2020;889:173644.
Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS, et al. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection. 2021;49(3):401-10.
Dashti-Khavidaki S, Khalili H, Nourian A. Pharmacotherapy considerations in CKD patients with COVID-19, a narrative review. Iranian journal of kidney diseases. 2020;14(4):247-55.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020;383(19):1813-26.
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):641-8.
Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, et al. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep. 2021;6(1):206-10.
Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A valid warning or clinical Lore: an evaluation of safety outcomes of Remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrobial Agents and Chemotherapy. 2021;65(2):e02290-20.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice. 2012;120(4):c179-c84.
Decreased G. Definition and classification of CKD. Kidney Int. 2013;3:19-62.
Dubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, et al. Case report study of the first five COVID-19 patients treated with remdesivir in France. International journal of infectious diseases. 2020;98:290-3.
Peyko V, Ladd H, Cutrona A. The safe administration of remdesivir in a patient with acute kidney injury requiring hemodialysis. Case reports in infectious diseases. 2020;2020.
Pettit NN, Pisano J, Nguyen CT, Lew AK, Hazra A, Sherer R, et al. Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? Clinical Infectious Diseases. 2021;73(11):e3990-e5.
Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, et al. Safety of remdesivir in patients with acute kidney injury or CKD. Kidney international reports. 2021;6(1):206.
Aiswarya D, Arumugam V, Dineshkumar T, Gopalakrishnan N, Lamech TM, Nithya G, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. Kidney international reports. 2021;6(3):586-93.
Xu Z, Tang Y, Huang Q, Fu S, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. BMC nephrology. 2021;22(1):1-10.
- Abstract Viewed: 298 times
- pdf Downloaded: 255 times